# Pragmatic Research on Diuretic Management in Early BPD (PRIMED) Pilot

> **NIH NIH R34** · CINCINNATI CHILDRENS HOSP MED CTR · 2024 · $228,044

## Abstract

PROJECT SUMMARY/ABSTRACT
Bronchopulmonary dysplasia (BPD) is the most frequent adverse outcome among infants born at <30 weeks
gestation and is associated with adverse respiratory and neurodevelopmental outcomes. Early BPD includes a
component of alveolar and interstitial edema resulting in reduced lung compliance. Some evidence suggests
that the use of loop diuretics, such as furosemide, in preterm infants > 3 weeks of age improves pulmonary
mechanics and oxygenation after 1 week of treatment; however, the evidence is weak because most studies
were not conducted in the current treatment era characterized by widespread surfactant and antenatal
corticosteroid use and data focuses mainly on short-term outcomes. Furthermore, diuretics have a range of
side effects including electrolyte abnormalities, osteopenia, potential ototoxicity, and nephrocalcinosis. Despite
weak evidence for their effectiveness and concerns over safety, diuretics are commonly used. There is a need
to strengthen the evidence-base regarding diuretic use in BPD with data that answers the current,
relevant clinical questions—whether an individual patient in the current treatment era will derive short-
term benefits from the treatment and whether the treatment is safe and effective in the long-term. We
designed a clinical trial that addresses prevailing clinical attitudes that some infants clinically benefit or are
“responders” by including a run-in period that examines individual patient short-term response using an
innovative N-of-1 trial design while also answering questions about the longer-term efficacy and safety of
chronic diuretic use by following the run-in N-of-1 trial with a placebo-controlled, parallel group randomized
controlled trial (RCT) of chronic diuretics among responders. The objective of this R34 application is to obtain
necessary and sufficient information to enable final decisions about the approach of the larger clinical trial
through the following specific aims: Aim 1: Estimate the number of responder infants available to enter the
parallel group RCT phase of the trial after the N-of-1 trial run-in period and Aim 2: Evaluate provider and
parent willingness to randomize responders to assess the potential dropout rate between run-in and
randomization. Accomplishing these aims is particularly important because the use of a formal N-of-1 trial
design as a run-in to a parallel group RCT is a unique and cutting-edge approach. Upon completion of these
aims, this pilot will provide a detailed understanding of the extent to which participants are able to complete the
N-of-1 trial and it will supply data on the percent of patients identified as “responders.” This will enable a more
accurate assessment of the available sample size entering the parallel group RCT phase of the trial. The pilot
will also provide the data necessary to determine the expected dropout rate between the run-in and parallel
group RCT phases due to reluctance to randomize a “responder” to furose...

## Key facts

- **NIH application ID:** 10756996
- **Project number:** 5R34HL158586-02
- **Recipient organization:** CINCINNATI CHILDRENS HOSP MED CTR
- **Principal Investigator:** Anna Maria Hibbs
- **Activity code:** R34 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $228,044
- **Award type:** 5
- **Project period:** 2023-01-01 → 2025-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10756996

## Citation

> US National Institutes of Health, RePORTER application 10756996, Pragmatic Research on Diuretic Management in Early BPD (PRIMED) Pilot (5R34HL158586-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10756996. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*